Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century

Archives of Internal Medicine

Volumn 168, Issue 5, 2008, Pages 469-476

  Pulte, Dianne ^a,b   Gondos, Adam ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SEX DIFFERENCE; TIME SERIES ANALYSIS; UNITED STATES; AGE; CANCER REGISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; RACE; RISK FACTOR; STATISTICS; SURVIVAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; LYMPHATIC METASTASIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RISK FACTORS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 41949131716     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2007.125     Document Type: Article

References (27)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality - All COD, Public-Use With State, Total US (1969-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007. http://www.seer.cancer.gov). Underlying mortality data provided by NCHS (http://www.cdc.gov/nchs). Accessed May 1, 2007.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195.
3. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339-2344.
4. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer. 2001;91(1):155-163.
5. Brenner H, Gefeller O, Hakulinen T. Period analysis for "up-to-date" cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004;40(3):326-335.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2006 Sub (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. http://www.seer.cancer.gov. Accessed May 1, 2007.
7. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164(7):689-696.
8. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78(9):2004-2010.
9. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002;20(3):826-832.
10. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol. 2002;31(2):456-462.
11. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
12. Henson DE, Ries LA. The relative survival rate. Cancer. 1995;76(10):1687-1688.
13. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations: Methodological Note No. 10. Bethesda, MD: National Cancer Institute; 1959.
14. Arias E. United States life tables, 2000. Natl Vital Stat Rep. 2002;51(3):1-38.
15. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22(23):4711-4716.
16. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064-3071.
17. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
18. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002;29(2) (suppl 6):18-22.
19. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005;46(11):1569-1573.
20. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
21. Wolf T, Brodt HR, Fichtlscherer S, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2005;46(2):207-215.
22. Diamond C, Taylor TH, Im T, Miradi M, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol. 2006;24(3):139-145.
23. Cronin DP, Harlan LC, Clegg LX, Stevens JL, Yuan G, Davis TA. Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol. 2005;23(2):73-81.
24. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92(15):1240-1251.
25. Berrios-Rivera JP, Fang S, Cabanillas ME, Cabanillas F, Lu H, Du XL. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol. 2007;30(2):163-171.
26. Mathew P, Elting L, Cooksley C, Owen S, Lin J. Cancer in an incarcerated population. Cancer. 2005;104(10):2197-2204.
27. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol. 2003;14(suppl 5):v61-v118.